秦 暢宏

Medicine & Life Sciences

1. Glioblastoma 100%
2. Glioma 81%
3. Mutation 30%
4. Neoplasms 30%
5. Isocitrate Dehydrogenase 29%
6. Loss of Heterozygosity 28%
7. Bevacizumab 26%
8. Oligodendroglioma 23%
9. Temozolomide 20%
10. Survival 19%
11. Brain Neoplasms 17%
12. Radiotherapy 14%
13. Neuroepithelial Neoplasms 13%
14. Pediatrics 13%
15. Ganglioglioma 11%
16. MicroRNAs 11%
17. Meningioma 11%
18. Typical Teratoid Rhabdoid Tumor 11%
19. Atypical Teratoid Tumor 11%
20. Japan 10%
21. Recurrence 9%
22. Chromosomes, Human, Pair 10 9%
23. Gadolinium 9%
24. Histones 8%
25. Craniotomy 8%
26. Diffusion Magnetic Resonance Imaging 8%
27. Scalp 8%
28. Retrospective Studies 7%
29. Cerebrospinal Fluid 7%
30. Freezing 7%
31. Pinealoma 7%
32. Magnetic Resonance Imaging 7%
33. Hydrocephalus 7%
34. Elderly 7%
35. Chromosomes 7%
36. Central Nervous System Neoplasms 7%
37. Clinical Deterioration 7%
38. Nimustine 7%
39. Perfusion 6%
40. Angiography 6%
41. Skull 6%
42. Central Nervous System 6%
43. Procarbazine 6%
44. Paresis 6%
45. APT 5%
46. Lymphoma 5%
47. Therapeutics 5%
48. Gene Expression 5%
49. Neoplasm Metastasis 5%